Literature DB >> 388798

Urease stones.

D P Griffith.   

Abstract

Urinary stones form as a consequence of urinary supersaturation. Supersaturation occurs as a result of elevated concentrations of urinary solutes. Dietary, metabolic, endocrine, hereditary, and infectious processes alter urinary solute concentrations. Struvite (MgNH4PO. 6H2O) and carbonate-apatite [Ca10(PO4)6CO3] stones form in urine that becomes supersaturated as a by-product of the hydrolysis of urea by the bacterial enzyme urease. Urease-induced stones manifest primarily as branched renal calculi and as bladder calculi. Conventional therapy has usually consisted of surgical removal of the stone combined with a short course of antimicrobial therapy. Such treatment is curative in about 50% of cases. Recurrent stone formation and progressive pyelonephritis occur in those who are not cured. Adjunctive medical treatment with acetohydroxamic acid or hydroxyurea lessens the risk of calculogenesis and decreases growth of residual stones in patients who are not cured by conventional therapy. Patients with urea-splitting urinary infection and renal stones have a major life-threatening disease. The morbidity and expense that result from this disease are great. Long-term (perhaps lifetime) chemotherapy with antimicrobial agents and/or urease-inhibiting drugs combined with judicious and expert surgical intervention can be expected to significantly improve the plight of these unfortunate patients.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 388798     DOI: 10.1007/bf00257208

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  10 in total

1.  UREASE CATALYSIS. II. INHIBITION OF THE ENZYME BY HYDROXYUREA, HYDROXYLAMINE, AND ACETOHYDROXAMIC ACID.

Authors:  W N FISHBEIN; P P CARBONE
Journal:  J Biol Chem       Date:  1965-06       Impact factor: 5.157

2.  Medical therapy of experimental infection stones.

Authors:  D L Lamm; S A Johnson; A M Friedlander; R F Gittes
Journal:  Urology       Date:  1977-11       Impact factor: 2.649

3.  Acetohydroxamic acid: clinical studies of a urease inhibitor in patients with staghorn renal calculi.

Authors:  D P Griffith; J R Gibson; C W Clinton; D M Musher
Journal:  J Urol       Date:  1978-01       Impact factor: 7.450

Review 4.  Struvite stones.

Authors:  D P Griffith
Journal:  Kidney Int       Date:  1978-05       Impact factor: 10.612

5.  The treatment of bilateral staghorn calculi of the kidneys.

Authors:  A Wojewski; T Zajaczkowski
Journal:  Int Urol Nephrol       Date:  1974       Impact factor: 2.370

6.  The fate of the unoperated staghorn calculus.

Authors:  M Singh; R Chapman; G C Tresidder; J Blandy
Journal:  Br J Urol       Date:  1973-12

7.  Urease inhibitors for hepatic coma. II. Comparative efficacy of four lower hydroxamate homologs in vitro and in vivo.

Authors:  W N Fishbein; J E Daly
Journal:  Proc Soc Exp Biol Med       Date:  1970-09

8.  Urease. The primary cause of infection-induced urinary stones.

Authors:  D P Griffith; D M Musher; C Itin
Journal:  Invest Urol       Date:  1976-03

9.  Hydroxyurea. I. Acute cell death in proliferating tissues in rats.

Authors:  F S Philips; S S Sternberg; H S Schwartz; A P Cronin; J E Sodergren; P M Vidal
Journal:  Cancer Res       Date:  1967-01       Impact factor: 12.701

10.  Hydroxyurea and infected stones.

Authors:  M J Smith
Journal:  Urology       Date:  1978-03       Impact factor: 2.649

  10 in total
  14 in total

Review 1.  Microbial ureases: significance, regulation, and molecular characterization.

Authors:  H L Mobley; R P Hausinger
Journal:  Microbiol Rev       Date:  1989-03

2.  Potential contribution of optional urease-positive bacteria to idiopathic urinary calcium stone formation. II. Microlith formation kinetics in a fermenter model of the urinary tract infected by optional urease-positive microorganisms.

Authors:  D B Leusmann; F Sabinski
Journal:  Urol Res       Date:  1996

3.  A preliminary study: the role of preoperative procalcitonin in predicting postoperative fever after mini-percutaneous nephrolithotomy in patients with a negative baseline urine culture.

Authors:  Deng Li; Minglei Sha; Lei Chen; Yinglong Xiao; Jun Lu; Yi Shao
Journal:  Urolithiasis       Date:  2019-02-12       Impact factor: 3.436

4.  Potential contribution of optional urease-positive bacteria to idiopathic urinary calcium stone formation. I. Expression of urease activity in bacteria from the urinary tract that are commonly classified as urease-negative.

Authors:  F Sabinski; D B Leusmann
Journal:  Urol Res       Date:  1996

5.  Visualization of Proteus mirabilis within the matrix of urease-induced bladder stones during experimental urinary tract infection.

Authors:  Xin Li; Hui Zhao; C Virginia Lockatell; Cinthia B Drachenberg; David E Johnson; Harry L T Mobley
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

6.  Canine struvite urolithiasis.

Authors:  J S Klausner; C A Osborne; D P Griffith
Journal:  Am J Pathol       Date:  1981-03       Impact factor: 4.307

7.  Bis(aminomethyl)phosphinic Acid, a Highly Promising Scaffold for the Development of Bacterial Urease Inhibitors.

Authors:  Katarzyna Macegoniuk; Anna Dziełak; Artur Mucha; Łukasz Berlicki
Journal:  ACS Med Chem Lett       Date:  2014-12-11       Impact factor: 4.345

8.  Proteus mirabilis genes that contribute to pathogenesis of urinary tract infection: identification of 25 signature-tagged mutants attenuated at least 100-fold.

Authors:  Laurel S Burall; Janette M Harro; Xin Li; C Virginia Lockatell; Stephanie D Himpsl; J Richard Hebel; David E Johnson; Harry L T Mobley
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

9.  Pharmacokinetics of acetohydroxamic acid in patients with staghorn renal calculi.

Authors:  L Putcha; D P Griffith; S Feldman
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

10.  Struvite Urolithiasis in Long-Evans Rats.

Authors:  Jassia Pang; Tiffany M Borjeson; Nicola M A Parry; James G Fox
Journal:  Comp Med       Date:  2015-12       Impact factor: 0.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.